Stocky turns companies like JCR PHARMACEUTICAL CO into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 4552.T scores below-average on both growth (32/100) and value (33/100) metrics, indicating mediocre earnings power and expensive valuation relative to fundamentals. Leadership alignment at 59/100 suggests modest incentive alignment, and the Vulnerable profile signals structural business headwinds despite low immediate leverage.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for JCR PHARMACEUTICAL CO:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 25/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates JCR PHARMACEUTICAL CO (4552.T) at 25/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 4552.T scores below-average on both growth (32/100) and value (33/100) metrics, indicating mediocre earnings power and expensive valuation relative to fundamentals. Leadership alignment at 59/100 suggests modest incentive alignment,
4552.T's current Stocky Verdict is 25/100, placing it in the "Avoid" band. This composite combines a 33/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for JCR PHARMACEUTICAL CO yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
JCR PHARMACEUTICAL CO scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
JCR PHARMACEUTICAL CO's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to JCR PHARMACEUTICAL CO.
Sign up free and unlock the full analysis on 4552.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 4552.T in the app.
